NCCN Hematologic Congress

leukemia

Jerald P. Radich, MD, on Chronic-Phase CML: Optimizing Tyrosine Kinase Inhibitor Therapy

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center, discusses the best strategies for sequencing tyrosine kinase inhibitor therapy for chronic myeloid leukemia and treatment-free remi...

hematologic malignancies
immunotherapy

Frederick L. Locke, MD, on CAR T-Cell Therapy: Major Milestones

Frederick L. Locke, MD, of Moffitt Cancer Center, discusses the key studies behind the development of CAR T cells, major adverse events and management strategies, and the potential of this revolutiona...

multiple myeloma

Shaji K. Kumar, MD, on Multiple Myeloma: Treatment Update

Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses emerging therapeutic options for relapsed multiple myeloma and how best to sequence treatments.

lymphoma
immunotherapy

Reem Karmali, MD, on Lymphomas and CAR T-Cell Therapy

Reem Karmali, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses CAR T-cell therapy for relapsed/refractory DLBCL and other subtypes of lymphomas, ways to man...

multiple myeloma

Natalie S. Callander, MD, on Newly Diagnosed Multiple Myeloma: Expert Perspective

Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses key patient and clinical factors that influence first-line treatment choices, as well as the efficacy and tole...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.